GN-CORPORATION
19.10.2021 08:48:06 CEST | Business Wire | Press release
Alfred Patisenah and Daisy Ramadhani of School of Life Sciences and Technology, Indonesia, won the prestigious Fujio Cup Quiz (FCQ), an active knowledge gaining academic event of NCRM NICHE 2021, on stem cells and regenerative medicine, in a fiercely fought contest among teams representing NIMHANS, Bangalore, India and Kasturba Medical College, the defending champions. Rajalakshmi Engineering College represented by Vigneshwar Ranjan and Vasanta Vaarshini Umapathi came runners in this contest across in three stages with assignments and online live quizzing, conducted since 2006, every October to commemorate the inaugural anniversary of Nichi in Centre for Regenerative Medicine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018006087/en/
The virtual event had lectures by Prof. Gary Levy , founder, Training program in regenerative medicine, University of Toronto (www.regenmedcanada.com ) on lessons learnt during the pandemic and arenas of research for tackling future Covid-19 like viruses (https://www.springer.com/gp/book/9781461357759 ), Prof. Kazutoshi Mori , Kyoto University, a Lasker prize awardee (https://www.nature.com/articles/nm.3682 ) on unfolding protein response and endoplasmic reticulum stress (https://elifesciences.org/articles/60970 ) and Prof. Timothy Kieffer , University of British Columbia & CSO of Viacyte Inc., on encapsulated pancreatic islet cell transplantation for diabetes (https://doi.org/10.3389/fendo.2021.642152 ). Covid-19 related research were presented by Dr. Tomohiko Kisaka, Hiroshima University, Dr. Stanley Jeremiah, Yokohama City University (https://jamanetwork.com/journals/jama/fullarticle/2765837 ), Dr. K. Raghavan, JAICARE, Madurai, India (https://www.sciencedirect.com/science/article/pii/S0753332221010271 ), Dr. K. Ramesh Shankar, NHS Trust - Lincolnshire Partnership, London United Kingdom (https://www.jns-journal.com/article/S0022-510X(21)00248-3/fulltext ) and Dr Dedeepiya Devaprasad, who spoke on BREW-COCO method for early prediction of worsening outcome in Covid-19. Prof. Jurgen Hescheler, University of Cologne, Germany, Prof. Naoki Yamamoto, Emeritus Professor, National Centre for Global health and Medicine, Tokyo, Japan and Prof. Pushkala Subramaniam, TN MGR Medical University, India, moderated.
NCRM NICHE an inter-disciplinary event cum innovation platform, spearheading development of novel solutions for Non-alcoholic steatohepatitis (NASH or NAFLD : https://doi.org/10.1101/2021.07.08.451700 ) and for managing neurodevelopmental disorders like Autism Spectrum Disorders (https://doi.org/10.1101/2021.06.28.21259619 ), has started attracting multinational investors. Enso Healthcare DMCC, Dubai, UAE, who have partnered with GN Corporation for this active knowledge gaining academic event, being a part of Enso group, a global conglomerate with diverse interests is envisaging to develop path breaking solutions through futuristic research for prevention and management of lifestyle illnesses and in the domains of anti-aging and longevity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018006087/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Iconic Landmark Danjiang Bridge Opened to Redefine Taiwan18.5.2026 12:02:00 CEST | Press release
The Danjiang Bridge, one of Taiwan’s most significant recent public infrastructure projects, officially opened with a series of large-scale public events, transforming the bridge into a new cultural landmark and civic space. The program featured the “Danjiang Bridge Together Arts Festival,” immersive public activities, and a special performance of Light Chain by Cloud Gate Dance Theatre, symbolizing the integration of architecture, engineering, and the arts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517667930/en/ The Danjiang Bridge is an iconic landmark in Taiwan with global recognition. (Photo via Highway Bureau , Motc) Spanning the mouth of the Tamsui River, the bridge serves as both a major transportation project and a recognizable architectural landmark, establishing a new urban symbol for Taiwan. Designed by Zaha Hadid Architects, the project gained international attention throughout its development and was sel
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 09:00:00 CEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 09:00:00 CEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 09:00:00 CEST | Press release
Expanded availability of LogicMonitor within Deutsche Telekom’s managed services portfolio follows successful operational use in the UKSelect outcomes include reduced reporting times and proactive incident preventionExpansion extends across DACH, Benelux, and the Nordics LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Throug
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 09:00:00 CEST | Press release
ZH9 is very well tolerated with a favourable safety profile, and no dose-limiting toxicities or Grade ≥3 drug-related adverse events reported.ZH9 demonstrates 91% freedom-from-relapse in NMIBC patients who have reached study end.Company plans to run a larger phase 2 study across a range of patient populations spanning intermediate risk and high risk including CIS. Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom